Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
July, 2026
July 2026
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
2728293031  
Wolfgang Miesbach on FRONTIER2 Data: Mim8 Prophylaxis Achieves a Median ABR of Zero in Hemophilia A
Wolfgang Miesbach/LinkedIn
Jan 6, 2026, 08:13

Wolfgang Miesbach on FRONTIER2 Data: Mim8 Prophylaxis Achieves a Median ABR of Zero in Hemophilia A

Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on LinkedIn:

“FRONTIER2 delivers impressive ASH 52-week data presented by Lentz Steven: Adults and adolescents with haemophilia A maintained robust bleed protection with Mim8 prophylaxis, regardless of inhibitor status or prior treatment regimen:

  • Median ABR of zero across extension period (weeks 26-52)
    QW dosing: estimated mean ABR 1.28 [95% CI: 0.78–2.08]
    QM dosing: estimated mean ABR 1.54 [95% CI: 0.92–2.59]
  • Prior on-demand patients saw dramatic 97–99% ABR reduction
  • CFC prophylaxis patients achieved 42–48% further ABR reduction compared to prior treatment

Safety profile and over 270+ patient-years of exposure:

  •  No thromboembolic events
  •  No hypersensitivity reactions
  •  No coagulation abnormalities
  •  Injection-site reactions in <1% of administrations (all mild, transient)
  • 82–84% of AEs mild; 66–88% unrelated to Mim8sciencehub.novonordisk​

Anti-Mim8 antibodies in 7% of patients—all low/medium titer, zero clinical impact

What is Mim8?
MFactor VIIIa mimetic bispecific antibody bridges activated FIX/FX on platelet surfaces
Half-life: ~1 month (enables QW or QM dosing flexibility)
Potency: 13–18× more effective than emicizumab preclinically

Take away
96% completion rate through 52 weeks reflects both tolerability and patient satisfaction. The consistency of efficacy with sustained zero median bleeds across 6+ months—combined with minimal safety signals—establishes Mim8 as a durable, flexible prophylactic option for haemophilia A. FRONTIER4 extension study now enrolling.”

Wolfgang Miesbach on FRONTIER2 Data: Mim8 Prophylaxis Achieves a Median ABR of Zero in Hemophilia A

Read more posts from Wolfgang Miesbach on Hemostasis Today.

American Society of Hematology (ASH) ASH FRONTIER2 haemophilia A Health Hemostasis Hemostasis News Hemostasis Today Medicine Mim8 thrombosis Wolfgang Miesbach
NewsFeed